Share Name Share Symbol Market Type Share ISIN Share Description
Avacta LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 67.50p 66.00p 69.00p 67.50p 67.50p 67.50p 5,316.00 07:35:57
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.2 -5.6 -6.9 - 46.16

Avacta Share Discussion Threads

Showing 3276 to 3300 of 3300 messages
Chat Pages: 132  131  130  129  128  127  126  125  124  123  122  121  Older
DateSubjectAuthorDiscuss
19/2/2017
17:31
Dec2000..."getting out of control" is an overreaction! If you go back a few pages to my post 935 you will read some good exchanges in response to me putting a decent case that Avacta has been a perennial under-performer. The chart at the top of this thread paints a thousand words! Lentjes...If you also read back a few pages it will be clear that there is little evidence of me simply criticising any positive posts. I may challenge the specifics or general thrust, but on the whole and certainly compared to some threads, this one is 'very' measured, orderly and cordial! I am ultimately on the side of the private investor, and it's just unfortunate that some investors will not like any degree of criticism. I believe that even some good news flow has the potential to bring out sellers (if any buyers emerge!) i.e. there is a queue at the exit, because the door to that exit is routinely closed by the market makers. Hence the share price performance often reflects the one step forward and two back syndrome. Management suggest that recent progress has not been recognised in the shares....it's because there are many willing sellers stupid! Investors who are sellers and who ultimately have no faith in the management or what the management state! The fact is, alternatives to antibodies have been around for a very long time with some having been established since at least 1999, but antibodies are the ones that have flourished and the ultimate commercial breakthrough in therapeutics for non-antibody alternatives has still not arrived. In non-therapeutic applications antibodies also dominate, with many non-antibody alternatives now suggesting that their offerings are superior to antibodies, yet despite these apparent advantages and being available for a very long time, again a breakthrough in non-therapeutic applications has yet to emerge. Avacta are quick to announce a collaboration, but fail to announce when a collaboration has come to nothing, leaving us to try to work it out for ourselves! Here are some excerpts from one of my recent previous posts (965) - "Anyone with the slightest thought of Affimers disrupting the antibody market will be very disappointed as Antibodies and the plethora of alternatives will almost certainly coexist, but given the wide array of existing and emerging alternatives, the non-antibody market will not be controlled or dominated by any one technology! That's not to say alternatives to antibodies will not ultimately prove successful, but it is likely to be a highly fragmented market as they all have similar attributes, albeit some may command niche markets, which may prove enough financially, but in some situations niche might not provide the level of value inflection ultimately hoped for. Although I remain open minded, in my opinion it is unlikely that Affimers will prove to be particularly superior to anything else out there, and whilst there might be room for several protein scaffolds across the range of therapeutic and non-therapeutic applications, it appears that there will be far more than just a few alternatives vying for a slice of the same business. Furthermore, several of Avacta's previous collaborations have come to nothing (and did not get a mention in the AR), does this indicate similar in terms of increasing competitive offerings, or that Affimers failed to meet expectations? One would assume that it's one or a combination of both of them." (END) Recall that Avacta dropped the development of Affimer microarrays, despite predicting imminent revenues from such. So we have heard it all before regarding imminent revenues! I very reluctantly let that go at the time (albeit I did challenged the rationale/decision), but it is yet another example of failure to deliver on the promise/strategy. Given Avacta's past history, I think we can assume that the microarrays simply did not come up expectations, which implies (along with other failed collaborations) that Affimers are perhaps not as perfect as Avacta imply. I remain of the personal opinion that unless Avacta can delivery exceptionally strong revenue growth in 2017, they are likely to need to raise further funds in 2017. Perhaps especially so, given that some are predicting that with the introduction of MiFID II in January 2018 reshaping the landscape for "independent" research, it could become an increasingly difficult market for SMEs looking to raise capital.
wan
19/2/2017
13:16
It's easy to blame the management if things take time or don't work out. This is a different company from seven years past. The product either has value and will be proven in the near term or yes maybe something else comes along that's better. It's a 50/50 gamble however I do believe affirmers have there place. Market is fickle and untill we get a stream of hard data the market will stay fickle. My view is the Co. Have achieved some traction in the last few years. No one said this would be easy.
danatkins
19/2/2017
13:16
It's easy to blame the management if things take time or don't work out. This is a different company from seven years past. The product either has value and will be proven in the near term or yes maybe something else comes along that's better. It's a 50/50 gamble however I do believe affirmers have there place. Market is fickle and untill we get a stream of hard data the market will stay fickle. My view is the Co. Have achieved some traction in the last few years. No one said this would be easy.
danatkins
19/2/2017
09:29
dec2000 and others suggest you read back through the last 7 years results to see all the failures and broken promises. This company has not delivered and will never deliver and in my opinion it is down to very bad management.
poacher45
18/2/2017
13:26
Well done dec2000, you beet me to it Wan During your extensive research over several years nobody critised your post even though in your own words over recent weeks it all appears to have been bull sh*t and hype by Avacta and you fell for it hook line and sinker. Now for some reason you appear to critise any positive post about Avacta and coming across a little bitter & twisted. It's clear you are now totally anti Avacta but would suggest you should show the same respect that others gave yourself and if you are so disillioned with Avacta I would suggest it's time for you to jog on
lentjes
18/2/2017
13:12
Good post, thank you.
ffp
18/2/2017
11:58
This thread is getting out of control. As far as I can see, there are indeed a number of scaffolds.. and some of the companies that developed them have been acquired by others, some have gone on to be valuable in their own right (eg Molecular Partners) and some have recently done potentially significant deals with others (eg Pieris). We need to keep these things in context and even in perspective. We have to remember that some significant partners have done deals with Avacta (Moderna and Memorial Sloan Kettering) OK these are subject to performance but these organisations would not even bother to start unless they thought that Affimers had promise. Then we have to remember that the biggest shareholder is IP Group and they are not fools. Far from it. Also Avacta has reported good progress with the therapeutic Tx side of the business and we have the testimonial from Ramzi. Next remember that the Scientific Advisory Board consists of some very significant indeed eminent people who would not bother if they thought Affimers were a waste of time. Finally remember that the company has generated genuine revenue in the Reagents and Diagnostics space for paid-for projects with other biotech companies and Alistair has indicated that we will see the first proper revenue for Affimer powered products in 2017. My take is that it is very frustrating that it is taking time, but this is inevitable and what we need is patience. Also remember that the big institutions are not selling.. so the fall in the share price is due to private individuals selling and this happens because of the drip of bad comments in sites such as this!!! Lets have some patience and sense ! Then we will see the share price rise not fall!
dec2000
18/2/2017
10:18
Wan,if you read my thread ,you will see I am also dissatisfied with some aspects of the way Avacta has performed. However,Affimers do have their place,just have a look at the Patents. The big question is can Avacta roll out the technology. Therefore,Avacta remains a punt but it still could be a very good one!
lantanatony
17/2/2017
17:59
I am not a scientist (which I often declare), but I do make a significant effort to gain an in-depth understanding of the companies I invest in, including their technology, existing and emerging competition (all of which is not easy). At some point though we have to look much closer to home in terms good corporate governance and tangible delivery, including on the stated strategy. On these counts, and in my book at least, Avacta has failed miserably! Unique sometimes means niche and relatively small, but I would be interested to learn exactly what unique place you think Affimers have attained/secured thus far?
wan
17/2/2017
17:11
Wan I understand you are a property developer. However you come across like a senior Bio Chemist. Affimers do have their unique place in this broad marketplace.
lantanatony
17/2/2017
16:26
That doesn't mean that another scaffold can't do the same as Affimers. Unfortunately I have come across a number of people that thought that there were no competitors to Affimers....well they were wrong and there is even a scaffold technology based on Ubiquitin!
wan
17/2/2017
15:14
Dr Ramzi Ajjan "Having worked with Affimer technology for some time now I am absolutely astonished by what we can do with these molecules. We have been trying for years to reduce blood clot formation. However this is very challenging because clots are made up of a complex network of fibrin fibres and the cells get trapped in this network. If the network can be made less compact it is easier to break down.” “The work we have done with Affimer molecules simply would not have been possible with antibodies. The large number of Affimer reagents we screened would not have been technically possible using antibodies and we've now been able to identify new therapeutic targets.” I'm sure you've spoken to him doing your research, but if not, you should.
the drewster
17/2/2017
09:18
The Drewster...Affimer scaffolds are not unique per se, as there are many other available options in terms of other scaffolds/antibody mimetics (I have a lot of research to back that up!). Alternatives to antibodies (with apparent advantages over antibodies) have been around for a very long time (some nearly 20 years), but the lack of adoption suggests that antibody mimetics are not the panacea for medical science you appear to suggest, hence the distinct lack of adoption!
wan
17/2/2017
08:54
I hope it is nothing seriously untoward. Affimers offer a truly transformational opportunity for medical science, and it would be a real shame for that potential to be lost by some internal political bickering.
the drewster
17/2/2017
07:24
Thanks wan,there is something unsavoury happening here imho.I am extremely disappointed.
spekky
14/2/2017
14:55
Spekky...One of the other things that has previously annoyed me (and I did raise it), was the poor communications. To name but two; they sold Oxford Medical Diagnostics and did not see fit to announce it, they also did not see fit to announce that Paul Ko Ferrigno (PKF) became Director of External Collaborations from what was arguably a senior position as Chief Scientific Officer. Having checked Companies House, I can confirm that PKF resigned as a director of Avacta Life Sciences on 24th January 2017!
wan
14/2/2017
14:26
Yes,bit of a concern,he's not tweeting/blogging much these days either......
spekky
14/2/2017
07:57
I note that Paul Ko Ferrigno, who was the founding scientist and founder of Aptuscan and who went quietly from Chief Scientific Officer to Director of External Collaborations, has now disappeared from Avacta's management page.
wan
24/1/2017
08:50
wan - appreciate your thoughts. It's clearly enough of a fear to keep the share price at these lowly levels. As ever, time will tell.
the drewster
23/1/2017
16:13
Drewster...Previously Avacta's management assured, no insisted, that no further fund raising was necessary, only to announce yet another placing out of the blue and where existing shareholders were heavily diluted. So, yes I have heard that one before a 'number' of times where Avacta are concerned. Also, if Avacta is expecting to close at least one licensing deal in 2017, where further development might be necessary, it would not exactly be good timing to wait until 2018 when cash would last less than a year. Furthermore, I note from the Trading Statement (I use that term loosely!) the following - "The Company expects to provide the market with more information about the build-out of the immuno-oncology portfolio and the strategy for expanding the in-house pipeline in the next few months as well as report on key data from immunogenicity studies - the first such data indicating whether the Affimer technology and individual Affimers show immunogenicity in human models." Recall that the use of the proceeds from the last placing was quite specific - 3. Use of proceeds The net proceeds of the Placing are expected to be approximately GBP21.0 million, of which GBP8.5 million is expected to be invested in infrastructure, specifically on: -- moving the therapeutics team to larger facilities from its current facilities at the Bioscience Catalyst, Stevenage; and -- expanding the team to support internal programmes and research partnerships. The Directors expect to invest GBP12.5 million in in-house development programmes, in the following principal areas: -- pre-clinical development of a number of Affimer immune checkpoint inhibitors and getting the lead asset into the clinic; -- pre-clinical development of a family of Affimers that modulate blood clotting for the treatment of cardiovascular and bleeding disorders; -- further development of the enabling platform technologies - broadly applicable tools to enhance Affimer therapeutics and improve third parties' products: o bi-specifics for combine therapies and targeting; o Affimer-drug-conjugates (ADC); o serum half-life extension; and o formulation for topical and intra-cellular/liposomal delivery; and -- continuing to strengthen the intellectual property around the enabling platform and file on individual Affimers and their therapeutic effects http://uk.advfn.com/stock-market/london/avacta-AVCT/share-news/Avacta-Group-PLC-Conditional-Placing-to-Raise-up-t/67714283 (END) Expanding the in-house pipeline did not feature in the use of proceeds. So, it will be interesting to see how they will fund that expansion, but given their track record (and I can quote many examples!) and as I indicated previously, I would not be surprised to see funds raised in 2017.
wan
23/1/2017
14:18
The conversations around cash at the AGM gave assurances that all was fine for 2017 AND 2018 if need be. I'd be floored if there was a cash call in this calendar year.
the drewster
23/1/2017
07:06
The following has been on my radar for quite a while and is another alternative technology to antibodies, MIPs (Molecularly Imprinted Polymers) from a UK company, MIP Diagnostics Ltd and is very interesting, their CEO Dr Adrian Kinkaid is an ex Chief Commercial Officer from Avacta. The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing. They can withstand harsh chemical environments, such as high concentrations of organic solvents. MIPs have successfully been created and deployed against targets including proteins, peptides and other macromolecular structures, as well as smaller chemical entities such as toxins, drugs, their metabolites and commonly used biochemical species such as enzyme cofactors. Using the proprietary nanoMIP development process, MIP Diagnostics can provide a proven nanoMIP within just two weeks of receiving the target. No immune response is required and no animals are used in the manufacture of MIPs. They offer a custom service and they can provide a proven nanoMIP within just two weeks (sometimes less) of receiving the target. Their technology appears particularly well suited to a number of key areas that Avacta are also targeting - http://www.mip-dx.com/ http://www.mip-dx.com/custom-made-mips MIP Diagnostics are not a listed entity, but MIP Diagnostic has recently received follow-on investment from Mercia Fund Management (Mercia), a leading investment business in UK innovation and wholly-owned subsidiary of Mercia Technologies PLC (MERC). The investment follows the successful completion of key milestones, including the appointment of CEO Dr Adrian Kinkaid, and the development of an initial sales pipeline. One year into operations, MIP Diagnostics has managed to secure customers and is in initial discussions with several blue chip organisations. So this could be an interesting one to watch, especially if Mercia brings MIP on board as a full portfolio company. For the record, I own a shares in Mercia Technologies (MERC).
wan
21/1/2017
09:06
Well you have just about said it all wan. I agree he has just about run out of money yet again. The bit I like is losses will be as forecast. How many years ago was it when he forecast a profit for the next year. Alastair should this time be made to concentrate his mind by having to put all his assets including his house up as collateral. I suffered a massive bad debt and several other problems which I wont bore you with but I made my business successful. It is time he stopped wasting other peoples money. This company is just a liability.
poacher45
21/1/2017
06:52
Spekky...I think that a history of never delivering is more deserving! We have heard so many times what the next market approach/development will be, for example, Sensipod - never happened, build out a large catalogue of reagents - never happened, microarrays and even revenues expected from microarrays - never happened, a raft of new Animal Health tests - never happened. Now we have confirmation that ubiquitination has gone the same way too! I won't bore everyone with the raft of other quotations from Alastair regarding the rationale for Avacta's strategy of focusing on ubiquitin, but for those interested just search Avacta Ubiquitylation (or ubiquitination). And also look at the news flow from Ubiquigent - http://www.ubiquigent.com/news-and-events/ (where IP Group has a significant shareholding) and Ubiquigent also has collaboration with Ubiq-Bio....remember them? Alastair Smith, Chief Executive of Avacta said: “This is probably the most important landmark in the Affimer story so far. Avacta is continuing to build a toolkit for the study of ubiquitylation and will make them available as part of an on-line catalogue which will be launched during the summer of 2014. Despite huge efforts over the past ten years antibody companies have been unsuccessful in building libraries of ubiquitin specific antibodies. Within a few weeks we have generated Affimer binders to a specific ubiquitin chain. As a result of the recent financing and this collaboration with UbiQ, we now have the technology and resource and access to ubiquitin chains to create large libraries of ubiquitin specific Affimer reagents. I expect to see a strong collaboration develop in this area with UbiQ and for us to grow a flagship catalogue to serve this important application in the study of ubiquitylation”. https://www.avacta.com/news/avacta-announces-collaboration-ubiq-bio-bv As for the Trading Update as whole, it provided scant detail in terms of trading and was bloated out with recycled stuff. The management are starting the year with "great enthusiasm" shouldn't that be without question? In my opinion, the market is being primed for another placing during 2017, and even if they have announced a licensing deal (which is likely to have no up-fronts), it will almost certainly have to be a heavily discounted offer.
wan
20/1/2017
08:43
For the stage of the company, and the state of the industry, these guys are making good progress. It will take a number of years for their discoveries to be translated into large revenues, they are doing all the right things.
bonzo
Chat Pages: 132  131  130  129  128  127  126  125  124  123  122  121  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20170224 19:33:07